Advertisement

Clinical Rheumatology

, Volume 30, Issue 5, pp 703–706 | Cite as

Takayasu’s arteritis progression on anti-TNF biologics: a case series

  • Mohammed Osman
  • Stephen Aaron
  • Michelle Noga
  • Elaine Yacyshyn
Brief Report

Abstract

Takayasu’s arteritis (TA) is a rare granulomatous vasculitic disease that affects the aorta and its major branches. Recent studies have suggested that anti-TNFα biological therapies are highly effective in treating TA refractory to conventional immunosuppressive therapy. We describe two patients with TA: one with progressive TA despite management with two different anti-TNFα agents, infliximab and adalimumab, and another who developed TA while treated with infliximab for the management of pre-existing Crohn’s disease. From our observations, we believe that a multicentered randomized study should be designed to assess the extent of resistance to these agents when different therapeutic doses are employed for managing TA.

Keywords

Anti-TNF biologics Crohn’s disease Infliximab Takayasu’s arteritis 

Notes

Disclosures

None.

References

  1. 1.
    Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–5167PubMedCrossRefGoogle Scholar
  2. 2.
    Reny JL et al (2003) Association of Takayasu’s arteritis and Crohn’s disease: results of a study on 44 Takayasu patients and review of the literature. Ann Med Interne (Paris) 154(2):85–90Google Scholar
  3. 3.
    Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21(1):3–9PubMedCrossRefGoogle Scholar
  4. 4.
    Maffei S et al (2009) Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 13(1):63–65PubMedGoogle Scholar
  5. 5.
    Molloy ES et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567–1569PubMedCrossRefGoogle Scholar
  6. 6.
    Filocamo G et al (2008) Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr 153(3):432–434PubMedCrossRefGoogle Scholar
  7. 7.
    Wolbink GJ et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707PubMedCrossRefGoogle Scholar
  8. 8.
    St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459PubMedCrossRefGoogle Scholar
  9. 9.
    Wolbink GJ et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715PubMedCrossRefGoogle Scholar
  10. 10.
    Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608PubMedCrossRefGoogle Scholar
  11. 11.
    Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 69(5):817–821PubMedCrossRefGoogle Scholar
  12. 12.
    El-Matary W, Persad R (2009) Takayasu’s aortitis and infliximab. J Pediatr 155(1):151PubMedGoogle Scholar
  13. 13.
    Farrant M et al (2008) Takayasu’s arteritis following Crohn’s disease in a young woman: any evidence for a common pathogenesis? World J Gastroenterol 14(25):4087–4090PubMedCrossRefGoogle Scholar
  14. 14.
    Levitsky J, Harrison JR, Cohen RD (2002) Crohn’s disease and Takayasu’s arteritis. J Clin Gastroenterol 34(4):454–456PubMedCrossRefGoogle Scholar
  15. 15.
    Owyang C et al (1979) Takayasu’s arteritis in Crohn’s disease. Gastroenterology 76(4):825–828PubMedGoogle Scholar
  16. 16.
    Friedman CJ, Tegtmeyer CJ (1979) Crohn’s disease associated with Takayasu’s arteritis. Dig Dis Sci 24(12):954–958PubMedCrossRefGoogle Scholar
  17. 17.
    Johnston SL, Lock RJ, Gompels MM (2002) Takayasu arteritis: a review. J Clin Pathol 55(7):481–486PubMedGoogle Scholar
  18. 18.
    Karlinger K et al (2000) The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 35(3):154–167PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Mohammed Osman
    • 1
  • Stephen Aaron
    • 1
  • Michelle Noga
    • 2
  • Elaine Yacyshyn
    • 1
  1. 1.Division of Rheumatology, Department of Medicine562 HMRC University of AlbertaEdmontonCanada
  2. 2.Department of Radiology and Diagnostic ImagingUniversity of AlbertaEdmontonCanada

Personalised recommendations